Consistent with the discovery and validation cohort 1 study, the plasma ofCS-CD44 performed well to distinguish malignant cancer, except for non-Hodgkin’s lymphoma and hepatocellular carcinoma. This evidence concerns the gene CD44 and non-Hodgkin lymphoma.